[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cervical-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":334},"Cervical Carcinoma",186,156,[8,16,22,29,36,42,47,53,59,65,71,77,83,89,95,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,192,198,204,210,216,222,228,234,240,246,252,258,264,269,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06315257","A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients",[12],"Phase 1","RECRUITING","2026-08-26T02:18:58.958025Z","2026-06-16T05:54:07.916994Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06109870","Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening",[],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.714631Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05838521","A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer",[26],"Phase 2","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.667759Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04683653","Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer",[33],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:29.483567Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06331468","Hypofractionated Radiochemotherapy",[26],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:29.465215Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":40,"content_modified":46},"NCT05758688","PROton Therapy for Post Surgical Treatment of GYNecologic Cancer",[26],"2026-05-05T02:43:29.388258Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07022470","Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).",[26],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:29.321794Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06157151","PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer",[26],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:29.077130Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT04831580","A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer",[],"2026-08-26T02:15:30.699880Z","2026-05-05T02:43:29.042295Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06925724","A Study of Ivonescimab in People With Endometrial and Cervical Cancers",[26],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.562258Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT07415681","GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries",[26],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.558894Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06191133","Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:28.478742Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT04567771","Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer",[],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:28.348364Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT06538337","Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers",[],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.812635Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":100,"content_modified":101},"NCT07061977","Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer",[99],"Phase 3","2026-08-26T02:17:10.213717Z","2026-05-05T02:43:27.797236Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06266338","Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)",[26],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.304598Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04016389","FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery",[],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.092268Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07216703","A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036\u002FTroFuse-036\u002FGOG-3123\u002FENGOT-cx22)",[99],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:27.076894Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06079671","Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)",[99],"2026-08-26T02:19:21.761002Z","2026-05-05T02:35:31.909501Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT04865887","Pembrolizumab and Lenvatinib in Advanced Cervical Cancer",[26],"2026-08-26T02:16:24.970704Z","2026-05-05T02:35:31.719186Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT06529809","Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer",[33],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.704965Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05197881","Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix",[],"2026-08-26T02:15:25.633039Z","2026-04-29T02:57:57.072933Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06686043","HPV Vaccine, Imiquimod, and Metformin Combination Trial",[26],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.177850Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06319963","A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer",[33],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.173901Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT07070232","A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",[33],"2026-08-26T02:18:30.351130Z","2026-07-24T01:27:14.894336Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",[33],"2026-08-26T02:15:38.131683Z","2026-07-24T01:27:14.891188Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[12],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05684965","XTX301 in Patients With Advanced Solid Tumors",[33],"2026-08-26T02:17:30.961790Z","2026-07-05T05:32:16.814936Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT05686226","E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",[26],"2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.812867Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[33],"2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT05579366","Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01\u002F PRO1184-001)",[33],"2026-08-26T02:17:02.694423Z","2026-07-05T05:32:16.807199Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT05483491","KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",[12],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.806172Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV",[12],"2026-08-26T02:17:27.435233Z","2026-06-18T12:24:02.872345Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[26],"2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[33],"2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT07578571","A Phase 1 Study of IM-1617 in Participants With Advanced Cancer",[12],"2026-08-26T02:18:48.678868Z","2026-05-29T15:36:40.196396Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[12],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06330064","A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",[26],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.734746Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.659697Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[26],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT06444815","A Study of VET3-TGI in Patients With Solid Tumors",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.507169Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT06239194","Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors",[33],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.493268Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":40,"content_modified":268},"NCT06677190","Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin",[26],"2026-05-05T02:43:29.398237Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06389123","Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas",[12],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.368418Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT07223424","Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",[26],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:29.166586Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT07524322","Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:28.715467Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT05983432","Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors",[12],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.678419Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06910657","IDOV-Immune for Advanced Solid Tumors",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.638930Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT04038619","Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",[12],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.626402Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors",[33],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.621667Z",[312,316,320,324,327,330],{"biomarker":313,"count":314,"slug":315},"HPV",13,"hpv",{"biomarker":317,"count":318,"slug":319},"MSI1 Gene",5,"msi1-gene",{"biomarker":321,"count":322,"slug":323},"ERBB2 Gene",4,"erbb2-gene",{"biomarker":325,"count":322,"slug":326},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":328,"count":322,"slug":329},"Programmed Cell Death 1 Ligand 1","programmed-cell-death-1-ligand-1",{"biomarker":331,"count":332,"slug":333},"BRAF Gene",3,"braf-gene",[335,339,343,347,351,355,359,363,367,371,375,379,382,385,389,392,396,399,403,407,411,414,418,422],{"state":336,"count":337,"slug":338},"Texas",78,"texas",{"state":340,"count":341,"slug":342},"California",59,"california",{"state":344,"count":345,"slug":346},"Florida",46,"florida",{"state":348,"count":349,"slug":350},"New York",40,"new-york",{"state":352,"count":353,"slug":354},"Ohio",34,"ohio",{"state":356,"count":357,"slug":358},"Virginia",33,"virginia",{"state":360,"count":361,"slug":362},"Pennsylvania",29,"pennsylvania",{"state":364,"count":365,"slug":366},"Massachusetts",28,"massachusetts",{"state":368,"count":369,"slug":370},"Tennessee",27,"tennessee",{"state":372,"count":373,"slug":374},"Georgia",24,"georgia",{"state":376,"count":377,"slug":378},"Michigan",23,"michigan",{"state":380,"count":377,"slug":381},"Minnesota","minnesota",{"state":383,"count":377,"slug":384},"North Carolina","north-carolina",{"state":386,"count":387,"slug":388},"Illinois",21,"illinois",{"state":390,"count":387,"slug":391},"New Jersey","new-jersey",{"state":393,"count":394,"slug":395},"Colorado",19,"colorado",{"state":397,"count":394,"slug":398},"Washington","washington",{"state":400,"count":401,"slug":402},"Missouri",18,"missouri",{"state":404,"count":405,"slug":406},"Maryland",17,"maryland",{"state":408,"count":409,"slug":410},"Arizona",16,"arizona",{"state":412,"count":409,"slug":413},"Utah","utah",{"state":415,"count":416,"slug":417},"Oregon",15,"oregon",{"state":419,"count":420,"slug":421},"Oklahoma",14,"oklahoma",{"state":423,"count":314,"slug":424},"Alabama","alabama"]